Your browser doesn't support javascript.
loading
Pattern and implications of neurological examination findings in autosomal dominant Alzheimer disease.
Vöglein, Jonathan; Franzmeier, Nicolai; Morris, John C; Dieterich, Marianne; McDade, Eric; Simons, Mikael; Preische, Oliver; Hofmann, Anna; Hassenstab, Jason; Benzinger, Tammie L; Fagan, Anne; Noble, James M; Berman, Sarah B; Graff-Radford, Neill R; Ghetti, Bernardino; Farlow, Martin R; Chhatwal, Jasmeer P; Salloway, Stephen; Xiong, Chengjie; Karch, Celeste M; Cairns, Nigel; Perrin, Richard J; Day, Gregory; Martins, Ralph; Sanchez-Valle, Raquel; Mori, Hiroshi; Shimada, Hiroyuki; Ikeuchi, Takeshi; Suzuki, Kazushi; Schofield, Peter R; Masters, Colin L; Goate, Alison; Buckles, Virginia; Fox, Nick C; Chrem, Patricio; Allegri, Ricardo; Ringman, John M; Yakushev, Igor; Laske, Christoph; Jucker, Mathias; Höglinger, Günter; Bateman, Randall J; Danek, Adrian; Levin, Johannes.
Afiliación
  • Vöglein J; Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Franzmeier N; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Morris JC; Institute for Stroke and Dementia Research, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Dieterich M; Washington University School of Medicine, Saint Louis, Missouri, USA.
  • McDade E; Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Simons M; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Preische O; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
  • Hofmann A; German Center for Vertigo and Balance Disorders, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Hassenstab J; Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Benzinger TL; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Fagan A; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
  • Noble JM; Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
  • Berman SB; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
  • Graff-Radford NR; Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
  • Ghetti B; Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Farlow MR; Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Chhatwal JP; Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Salloway S; Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, and Gertrude H. Sergievsky Center, Columbia University Irving Medical Center, New York City, New York, USA.
  • Xiong C; University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Karch CM; Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Cairns N; Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Perrin RJ; Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Day G; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Martins R; Butler Hospital, Providence, Rhode Island, USA.
  • Sanchez-Valle R; Division of Biostatistics, Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Mori H; Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Shimada H; Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Ikeuchi T; Medical School and Living Systems Institute, University of Exeter, Exeter, UK.
  • Suzuki K; Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Schofield PR; Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Masters CL; Edith Cowan University, Joondalup, Western Australia, Australia.
  • Goate A; Service of Neurology, Hospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Buckles V; Osaka City University Medical School, Abenoku, Osaka, Japan.
  • Fox NC; Osaka City University Medical School, Abenoku, Osaka, Japan.
  • Chrem P; Brain Research Institute, Niigata University, Niigata, Japan.
  • Allegri R; University of Tokyo, Tokyo, Japan.
  • Ringman JM; Neuroscience Research Australia, Sydney, Australia.
  • Yakushev I; School of Medical Sciences, University of New South Wales, Sydney, Australia.
  • Laske C; Florey Institute, University of Melbourne, Victoria, Australia.
  • Jucker M; Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
  • Höglinger G; Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Bateman RJ; Dementia Research Centre, Institute of Neurology, University College London, London, UK.
  • Danek A; FLENI, Buenos Aires, Argentina.
  • Levin J; FLENI, Buenos Aires, Argentina.
Alzheimers Dement ; 19(2): 632-645, 2023 02.
Article en En | MEDLINE | ID: mdl-35609137
ABSTRACT

INTRODUCTION:

As knowledge about neurological examination findings in autosomal dominant Alzheimer disease (ADAD) is incomplete, we aimed to determine the frequency and significance of neurological examination findings in ADAD.

METHODS:

Frequencies of neurological examination findings were compared between symptomatic mutation carriers and non mutation carriers from the Dominantly Inherited Alzheimer Network (DIAN) to define AD neurological examination findings. AD neurological examination findings were analyzed regarding frequency, association with and predictive value regarding cognitive decline, and association with brain atrophy in symptomatic mutation carriers.

RESULTS:

AD neurological examination findings included abnormal deep tendon reflexes, gait disturbance, pathological cranial nerve examination findings, tremor, abnormal finger to nose and heel to shin testing, and compromised motor strength. The frequency of AD neurological examination findings was 65.1%. Cross-sectionally, mutation carriers with AD neurological examination findings showed a more than two-fold faster cognitive decline and had greater parieto-temporal atrophy, including hippocampal atrophy. Longitudinally, AD neurological examination findings predicted a significantly greater decline over time.

DISCUSSION:

ADAD features a distinct pattern of neurological examination findings that is useful to estimate prognosis and may inform clinical care and therapeutic trial designs.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer / Disfunción Cognitiva Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Alzheimers Dement Año: 2023 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer / Disfunción Cognitiva Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Alzheimers Dement Año: 2023 Tipo del documento: Article País de afiliación: Alemania
...